Product successfully added to your shopping cart
translation missing: en.products.wishlist.added_to_wishlist
There are item(s) in your cart
FREE SHIPPING with purchase of $99 or more! Use code FREESHIP at checkout
Galleri® Multi-Cancer Early Detection Test By Grail
The Galleri multi-cancer early detection test detects more than 50 types of cancer, many of which are not commonly screened for today. With a simple blood draw, the Galleri test provides early detection insights that help you be proactive about your health.
Multi-cancer early detection enables you to proactively test for many cancers, increasing the chances of finding cancer early.
Beating cancer starts with knowing you have it
Finding cancer early is important to improve treatment outcomes and survival.
The vast majority of cancers show no symptoms until later stages, when treatment options may be limited. Today, many cancers are found too late, when outcomes are often deadly.
Finding cancer early is important
Thinking about the possibility of cancer can be overwhelming, but taking steps to find cancer early can help you feel more in control. Often, the earlier that cancer can be found, the higher the chance of better outcomes.
In studies, the Galleri test has shown the ability to detect multiple types of cancers through a single blood draw. Most of these cancers cannot be detected through current screening paradigms. When cancer signal was detected, the Galleri test localized the cancer signal with high accuracy, helping inform next steps to diagnosis.
The Galleri test is intended to be complementary to, and not a replacement of, U.S. guideline-recommended cancer screening.
Galleri is a trademark of GRAIL, LLC.
Who are we
In pursuit of innovation to solve healthcare’s most important challenges
We are a healthcare company focused on saving lives and improving health by pioneering new technologies for early cancer detection. We have built a multi-disciplinary organization of scientists, engineers, and physicians and we are using the power of next-generation sequencing (NGS), population-scale clinical studies, and state-of-the-art computer science and data science to overcome one of medicine’s greatest challenges.
Our mission is to detect cancer early, when it can be cured. We are working to change the trajectory of cancer mortality and bring stakeholders together to adopt innovative, safe, and effective technologies that can transform cancer care.